Healthcare Services APAC

APAC Biologics CDMO Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Biologics CDMO Market Industry Trends and Forecast to 2034: Segmented by (Product, Service, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.82 Bn Placeholder estimate
Estimate 2025 $5.42 Bn 20% of the global market
Projected 2034 $15.53 Bn 186.3% Adds $10.11 Bn over 9 forecast years
CAGR 2025–2034 12.4% Faster than 69% of 107 Healthcare Services markets here
Key players 6 +1
  • APAC is 20.01% of the global market.
  • Among regions, the largest is North America at $11.42 Bn.
  • Fastest growing: Africa at 12.8% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$10.11 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Biologics CDMO Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.82 Bn — —
2025 (base) $5.42 Bn +$598.2 Mn —
2026 (forecast) $6.10 Bn +$672.4 Mn +12.4%
2027 (forecast) $6.85 Bn +$755.8 Mn +26.3%
2028 (forecast) $7.70 Bn +$849.5 Mn +42%
2029 (forecast) $8.66 Bn +$954.8 Mn +59.6%
2030 (forecast) $9.73 Bn +$1.07 Bn +79.4%
2031 (forecast) $10.93 Bn +$1.21 Bn +101.6%
2032 (forecast) $12.29 Bn +$1.36 Bn +126.7%
2033 (forecast) $13.81 Bn +$1.52 Bn +154.8%
2034 (forecast) $15.53 Bn +$1.71 Bn +186.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Biologics CDMO Market Analysis at a glance
Market size, 2025$5.42 Bn placeholder estimate
Forecast, 2034$15.53 Bn placeholder estimate
Growth (CAGR), 2025–203412.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledBiologics Contract Development and Manufacturing (CDMO)
SegmentsProduct, service and end user (see all)
Key playersLonza Ltd, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings Corporation, Catalent and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Biologics CDMO Market Analysis Executive Summary

Biologics CDMOs develop and manufacture antibodies, proteins and vaccines for pharma and biotech companies.

Key segments of the biologics CDMO market include product (Monoclonal Antibodies, Recombinant Proteins and Vaccines) and service (Process Development, Clinical Manufacturing and Commercial Manufacturing).

Bar chart: Asia Pacific Biologics CDMO market size, 2024–2034, placeholder estimates. $4.82 Bn in 2024, $5.42 Bn in 2025 and $15.53 Bn in 2034, 12.4% CAGR.
Asia Pacific Biologics CDMO market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Biologics CDMO Market Dynamics

Market Growth Drivers

Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biologics CDMO market. Many companies now outsource work they used to do in-house.

Opportunity

Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the biologics CDMO market room to grow.

Market Restraints

Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the biologics CDMO market.

Competitive Landscape for Biologics CDMO Market in APAC

The biologics CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Biologics CDMO Market in APAC

Biologics CDMO in APAC: payment

How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[1], basic medical insurance (China)⁠[2], the Hospital Authority (Hong Kong)⁠[3], Ayushman Bharat PM-JAY (India)⁠[4], public health insurance (Japan)⁠[5], subsidised public care (Malaysia)⁠[6], Pharmac (New Zealand)⁠[7], PhilHealth (Philippines)⁠[8], MediShield Life (Singapore)⁠[9] and the Universal Coverage Scheme (Thailand)⁠[10].

[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] Hospital Authority. Checked 14 Nov 2026.

[4] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[5] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[6] Ministry of Health Malaysia. Checked 14 Nov 2026.

[7] Pharmac. Checked 14 Nov 2026.

[8] PhilHealth. Checked 14 Nov 2026.

[9] CPF Board, MediShield Life. Checked 14 Nov 2026.

[10] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how biologics CDMO services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.

Public data, with sources

Biologics CDMO in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Biologics CDMO market in Asia Pacific?
Placeholder estimate: about $5.42 Bn in 2025, rising to about $15.53 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Biologics CDMO market in Asia Pacific growing?
Placeholder estimate: about 12.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Biologics CDMO market report cover?
The report splits the market by product (Monoclonal Antibodies, Recombinant Proteins, Vaccines, ADCs), service (Process Development, Clinical Manufacturing, Commercial Manufacturing, Fill-Finish) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Biologics CDMO market?
Key players include Lonza Ltd, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings Corporation, Catalent and AGC Biologics.
What is driving the Biologics CDMO market?
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biologics CDMO market. Many companies now outsource work they used to do in-house.
Back to Catalogue

Related Healthcare Services reports in APAC

See all

Related on drug development and manufacturing and biologics and biosimilars

See the topic